Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Las Palmas De Gran Canaria – page 2

309 clinical trials in Las Palmas De Gran Canaria, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Las Palmas De Gran Canaria at a glance
309
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

309 trials in Las Palmas De Gran Canaria

Open in trial search

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Non-small cell lung cancer

Recruiting

A study of MK-1084 and pembrolizumab for patients with resected KRAS G12C-mutant non-small cell lung cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Transitional cell carcinoma

Recruiting

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Small cell lung cancer extensive stage

Recruiting

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Chronic graft versus host disease

Recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Arteriosclerosis

Recruiting

Effect of Lepodisiran on Coronary Plaque in Adults with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease or High Risk for First Event

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:LY3819469 sodium
  • Sponsor:Eli Lilly & Co.

Follicular lymphoma

Recruiting

Study of AZD0486 plus rituximab versus standard chemotherapy drug combination in previously untreated follicular lymphoma patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Bladder cancer

Recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Astellas Pharma Global Development Inc.

Glomerulonephritis membranoproliferative+1

Recruiting

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Vitiligo

Recruiting

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Small cell lung cancer extensive stage

Recruiting

Study of MK-6070 drug combination in first-line extensive-stage small cell lung cancer patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Las Palmas De Gran Canaria

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple cancer types, including studies of novel therapeutic approaches for leukemia, lung cancer, and breast cancer.

  • BCR-ABL1+ Chronic Myeloid Leukemia treatments
  • Advanced bladder cancer therapies
  • Non-small cell lung cancer interventions

Research emphasizes combination therapies and targeted treatments to improve patient outcomes.

02 Autoimmune Conditions

Comprehensive studies investigating treatments for inflammatory diseases and autoimmune disorders, with particular focus on novel biological therapies.

  • Multiple sclerosis treatment innovations
  • Crohn's disease management
  • Ulcerative colitis therapies

Advanced clinical trials evaluating new therapeutic approaches for chronic inflammatory conditions.

03 Immunology Studies

Cutting-edge research in immunotherapy and allergic conditions, exploring new treatment modalities and therapeutic combinations.

  • Allergic rhinitis treatments
  • Graft-versus-host disease therapies
  • Immunotherapy combinations

Innovative approaches focusing on immune system modulation for various conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.